ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ACOR Stock Price » ACOR Stock News

Acorda Therapeutics Share News

 Acorda Therapeutics (mm) Stock Price
ACOR Stock Price
 Acorda Therapeutics (mm) Stock Chart
ACOR Stock Chart
 Acorda Therapeutics (mm) Stock News
ACOR Stock News
 Acorda Therapeutics (mm) Company Information
ACOR Company Information
 Acorda Therapeutics (mm) Stock Trades
ACOR Stock Trades

Biogen Gets Letter Of Deficiency From Health Canada On Fampridine

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) has received a letter of deficiency from Health Canada for its application to sell the multiple sclerosis treatment fampridine in the country. The Weston, Mass., biotech company also recently received questions from the European Medicines Agency on an application to sell the same drug in the region. Biogen expects a decision later this month. The disclosures were made at the JPMorgan healthcare conference in San Francisco Tuesday by Chief Executive George Scangos. Scangos declined to comment on the letter or provide any further detail about the questions from the regulators. Fampridine helps improve walking in multiple sclerosis patients and is sold in the U.S. by Acorda Therapeutics Inc. (ACOR) under the name Ampyra. Separately, the company said that about 56,000 patients are using its MS drug Tysabri as of the end of December, an increase of 1,700 patients from fourth quarter and down from the 2,100 patients added in the third quarter. -By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com

Stock News for Acorda Therapeutics (ACOR)
DateTimeHeadline
07/30/201507:17:01Current Report Filing (8-k)
07/30/201506:01:00Acorda Provides Financial and Pipeline Update for 2015 Second...
07/24/201509:25:00Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma...
07/23/201507:00:00Acorda Therapeutics to Host Conference Call to Discuss Second...
07/22/201507:26:59Current Report Filing (8-k)
07/22/201507:00:00Acorda Awarded Grant to Study ARCUS® Technology in Respiratory...
07/02/201515:41:00Initial Statement of Beneficial Ownership (3)
06/24/201507:01:00Acorda Data on Inhaled Levodopa Therapy CVT-301 Recognized in...
06/16/201507:15:17Current Report Filing (8-k)
06/16/201507:00:00Acorda Presents Data on Inhaled Levodopa Therapy CVT-301 at International...
06/15/201507:32:00Acorda CEO Ron Cohen Named BIO Chairman for 2015-2016 Term
06/12/201508:29:37Current Report Filing (8-k)
06/11/201516:14:48Statement of Changes in Beneficial Ownership (4)
06/11/201516:14:19Statement of Changes in Beneficial Ownership (4)
06/11/201516:12:59Statement of Changes in Beneficial Ownership (4)
06/11/201516:12:07Statement of Changes in Beneficial Ownership (4)
06/11/201516:11:12Statement of Changes in Beneficial Ownership (4)
06/11/201516:09:02Statement of Changes in Beneficial Ownership (4)
06/11/201516:07:46Statement of Changes in Beneficial Ownership (4)
06/09/201514:07:49Amended Statement of Ownership (sc 13g/a)

Acorda Therapeutics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad